Bruce Woda to Follow-Up Studies
This is a "connection" page, showing publications Bruce Woda has written about Follow-Up Studies.
Connection Strength
0.072
-
Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget. 2016 Sep 13; 7(37):59976-59986.
Score: 0.023
-
Truong F, Smith BR, Stachurski D, Cerny J, Medeiros LJ, Woda BA, Wang SA. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res. 2009 Aug; 33(8):1039-46.
Score: 0.013
-
Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1648-52.
Score: 0.013
-
Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res. 2008 Apr; 32(4):553-8.
Score: 0.012
-
Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006 Jul; 7(7):556-64.
Score: 0.011